ORG 10172: a low molecular weight heparinoid anticoagulant with a long half‐life in man.
Open Access
- 1 June 1987
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 23 (6), 667-675
- https://doi.org/10.1111/j.1365-2125.1987.tb03100.x
Abstract
ORG 10172 is a heparinoid with mean molecular weight 6500 daltons. Intravenous bolus injections of ORG 10172 were compared with placebo and heparin injections in 91 separate studies in 83 healthy male subjects. 6400 units ORG 10172 produced a mean maximum change of 14.7 s in kaolin cephalin time (c.f. greater than 120 s for 5000 units heparin). Changes in prothrombin time were minimal (1.6 s for 6400 units ORG 10172 and 4.5 s after 5000 units heparin). A dose‐related increase in bleeding time occurred after ORG 10172 and at high doses (greater than 3200 units) some secondary bleeding, which was never serious, occurred at between 1 and 4 h after incision. A dose‐dependent reduction in ex vivo platelet adhesiveness was found at 10 min after ORG 10172 injection. ORG 10172 promoted a much smaller release of lipoprotein lipase as compared with heparin. The effect of ORG 10172 on plasma factor Xa activity (one measure of its action) was described by a biexponential decay with a mean distribution half‐life of 2.34 (s.e. mean 0.16) h and mean disposition half‐life of 17.6 (s.e. mean 1.1) h. It thus has a much longer duration of effect than heparin. There was a linear relationship of plasma anti‐Xa response to increasing dose although there was some variability only partly explained by differences in body weight or surface area. ORG 10172 administration by bolus intravenous injection was well tolerated and there was no evidence of adverse effects on clinical chemistry or haematology tests.This publication has 27 references indexed in Scilit:
- Circadian changes in anticoagulant effect of heparin infused at a constant rate.BMJ, 1985
- Use of a heparinoid in patients with hemorrhagic stroke and thromboembolic diseaseAnnals of Neurology, 1984
- USE OF A NEW HEPARINOID AS ANTICOAGULANT DURING ACUTE HAEMODIALYSIS OF PATIENTS WITH BLEEDING COMPLICATIONSThe Lancet, 1983
- Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasmaThrombosis Research, 1982
- Discordance between the anti-Xa activity and the antithrombotic activity of an ultra-low molecular weight heparin fractionThrombosis Research, 1982
- Clinical Pharmacokinetics of HeparinClinical Pharmacokinetics, 1980
- Anticoagulant Activities of High and Low Molecular Weight Heparin FractionsBritish Journal of Haematology, 1979
- HÆMORRHAGIC COMPLICATIONS OF HEPARIN THERAPYThe Lancet, 1977
- Heparin kinetics in venous thrombosis and pulmonary embolism.Circulation, 1976
- A specific method for serum lipase determinationClinica Chimica Acta; International Journal of Clinical Chemistry, 1966